For the latest news and information about the coronavirus pandemic, please visit the WHO website.
After the drug is approved, it will take some time to manufacture and distribute-not everyone can get the vaccine at once.
According to the “Washington Post” report, Robert Walker, head of the Department of Medicine at the University of California, San Francisco, said that by the end of this year, the United States may receive multiple vaccines. Only one year has passed since the discovery of SARS-CoV-2 (the official name of the virus that causes COVID-19 disease). Vaccine development usually takes decades.
However, obtaining one or more vaccines approved by the FDA through clinical trials is only the first step in the journey. The next step is to convince people to accept it. 63% of U.S. adults expressed concern about the safety of the coronavirus vaccine -40% of respondents were particularly worried about its rapid development. too According to the Harris poll on October 19, this method is very fast.
Currently, 59 coronavirus vaccines are in different stages of clinical trials and are almost ready to apply for approval. Most experts believe that by early 2021, we will be ready to distribute several sets, but life will not return to normal until 2022.
The FDA said in June that it will not approve any vaccine that expires at least half the time, but some scientists question whether this is effective enough. The hope is that in the fields of dozens of candidates, at least a few work more than half of the time.
Here, we will introduce you to the main news about the coronavirus vaccine, explain the position of the most promising candidates and who can get which vaccine. This article is updated frequently and is intended as a general overview, not a source of medical advice. If you want to learn more about coronavirus testing,.
Important COVID-19 vaccine news
The COVID vaccine is gaining momentum
Several accelerations are currently underway, such as the White House’s “Operation Warp Speed”, which aims to break through regulatory red tape to accelerate vaccine development, and prepare to distribute vaccines immediately after obtaining FDA approval. So far, the U.S. government has pledged more than $10 billion in funding to several vaccine manufacturers to secure a total of 800 million doses of vaccine.
Vaccines usually take about 10 to 15 years to develop and approve, including four phases of human trials. However, through “quick action”, approved vaccine projects can submit data to the FDA bit by bit, instead of submitting all the data for the four-phase trials at once.
At the same time, the plan is also starting to produce doses with financial support, while clinical trials are still ongoing. This means that if these vaccines are indeed approved, when they are approved, the vaccines already in stock will be ready to be distributed nationwide.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said: “I hope that by the second half of 2021, these companies will be able to provide the hundreds of millions of doses they promised.” He told Forbes in August. Until October, Fauci remained confident in such a timetable.
Promising coronavirus vaccines from the UK, US and China
Take a quick look at some of the leaders in the race to find a COVID-19 vaccine, including where the vaccine was developed, where it is being tested, and when scientists think they can be ready for widespread distribution (if known).
University of Oxford/AstraZeneca (UK): AstraZeneca has restarted testing of its vaccine, which started with 100,000 human volunteers in at least three countries. Lead researcher Dr. Sarah Gilbert initially stated that AstraZeneca’s goal is to be released in the fall of 2020. Although it may be optimistic at this point, it does not appear to be significantly delayed.
Hyundai (United States): The apparent melee with government regulators has delayed large-scale human testing, but the CEO of Modena told Barron that he still hopes the company will know whether the vaccine is safe and effective before Thanksgiving. He said that if anything, Moderna should be able to distribute it in early 2021.
Pfizer (United States): Although its four candidate COVID-19 vaccines are still in early human trials, two of them have been fast-tracked by the FDA. Pfizer’s goal is to distribute 100 million doses by 2020 and another 1.3 billion doses by 2021.
SinoVac (China): Currently, the vaccine has been tested in about 10,000 human volunteers in China and about 9,000 volunteers in Brazil, and will soon begin testing on about 1,900 test subjects in Indonesia. The CEO of SinoVac’s Indonesian partner BioPharma has stated that he expects the vaccine to be ready in early 2021.
Sinopharm (China): The state-owned company is currently testing about 15,000 volunteers in the Middle East, which is expected to last three to six months. Early results indicate that the drug is safe, at least somewhat effective. SinoPharm recently built a second facility to produce the vaccine, doubling its production capacity to approximately 200 million doses per year.
CanSino Biologics (China): CanSino’s vaccine will begin large-scale human trials this summer and has been approved for use by the Chinese military. The vaccine is based on a modified common cold virus, which some experts warn may make it less effective than other vaccines.
Will everyone have only one vaccine?
We may not know until next year, but Fauci suggested in a paper published in the journal Science on May 11 that several different vaccines produced and distributed by different laboratories may be needed to end the pandemic. He also said that he foresees that different vaccines will be used for different patient populations. For example, one vaccine is for the elderly or other high-risk patients, another is for healthy adults, and the other is for children.
What if we never find a coronavirus vaccine?
Coronaviruses are a large group of viruses. So far, there is no vaccine against them. Despite the encouraging early results, there is still no guarantee of vaccine production by 2021. According to a report by Reuters in April, statistically speaking, only about 6% of vaccine candidates can be marketed.
Early evidence suggests that the coronavirus does not seem to mutate as quickly or frequently as the influenza virus, and it is believed that the virus is not mutated enough to disrupt vaccine development, although our knowledge may change.
The longer we get vaccinated, the more likely the focus will shift to treatment, such as, Reportedly showing encouraging results, and Doctors say that in the most severe cases, this steroid can improve survival. Through effective treatments, many viruses that were once deadly are no longer the death penalty. For example, thanks to huge advances in treatment, HIV patients can now expect to have the same life expectancy as non-HIV positive patients.
Eventually, the global population may reach 60% to 70%Protecting those who are not immune is ultimately the goal of the vaccine.
The information contained in this article is for educational and information purposes only, and not for health or medical advice. If you have any questions about medical conditions or health goals, be sure to consult a doctor or other qualified healthcare provider.